CD168 (F374) polyclonal, anti-human
€305.00
In stock
SKU
BS9210
Background:
HA effects are mediated through two receptors, CD44 (also designated HCAM) and the receptor of hyaluronic acid mediated motility (RHAMM). RHAMM, also designated intracellular hyaluronic acid binding protein (IHABP) and CD168, is a matrix receptor, which is linked to the plasma membrane by a GPI anchor and regulates cell motility. RHAMM expression is upregulated in malignant lymphoid tissues and is subsequently implicated in tumor progression and metastasis formation, as well as signal transduction. Although still unclear, RHAMM is thought to exist as several isoforms ranging in size. A variant isoform, designated v4, is a protein that, when over-expressed, is thought to be the cause of transformation and metastasis formation in fibroblasts.
Alternative Name:
CD168, CD168 antigen, HMMR, HMMR, Hyaluronan mediated motility receptor, Hyaluronan-mediated motility receptor (RHAMM), IHABP, Intracellular hyaluronic acid-binding protein, MGC119494, MGC119495, OTTHUMP00000196920, Receptor for hyaluronan-mediated motility, RHAMM
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200
Specificity: CD168 (F374) polyclonal antibody detects endogenous levels of CD168 protein.
Immunogen:
Synthetic peptide, corresponding to amino acids 341-390 of Human CD168.
MW: ~ 85 kDa
Swis Prot.: O75330
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
HA effects are mediated through two receptors, CD44 (also designated HCAM) and the receptor of hyaluronic acid mediated motility (RHAMM). RHAMM, also designated intracellular hyaluronic acid binding protein (IHABP) and CD168, is a matrix receptor, which is linked to the plasma membrane by a GPI anchor and regulates cell motility. RHAMM expression is upregulated in malignant lymphoid tissues and is subsequently implicated in tumor progression and metastasis formation, as well as signal transduction. Although still unclear, RHAMM is thought to exist as several isoforms ranging in size. A variant isoform, designated v4, is a protein that, when over-expressed, is thought to be the cause of transformation and metastasis formation in fibroblasts.
Alternative Name:
CD168, CD168 antigen, HMMR, HMMR, Hyaluronan mediated motility receptor, Hyaluronan-mediated motility receptor (RHAMM), IHABP, Intracellular hyaluronic acid-binding protein, MGC119494, MGC119495, OTTHUMP00000196920, Receptor for hyaluronan-mediated motility, RHAMM
Application Dilution: WB: 1:500~1:1000, IHC: 1:50~1:200
Specificity: CD168 (F374) polyclonal antibody detects endogenous levels of CD168 protein.
Immunogen:
Synthetic peptide, corresponding to amino acids 341-390 of Human CD168.
MW: ~ 85 kDa
Swis Prot.: O75330
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review